详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Apelin-mediated deamidation of HMGA1 promotes tumorigenesis by enhancing SREBP1 activity and lipid synthesis

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory of Sichuan Province, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. [4]Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China. [5]Administration of Research Park, West China Hospital, Sichuan University, Chengdu, China. [6]Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： apelin glutamine deamidation HMGA1 lipid metabolism lung tumorigenesis

摘要：

Enhanced fatty acid synthesis provides proliferation and survival advantages for tumor cells. Apelin is an adipokine, which serves as a ligand of G protein-coupled receptors that promote tumor growth in malignant cancers. Here, we confirmed that apelin increased sterol regulatory element-binding protein 1 (SREBP1) activity and induced the expression of glutamine amidotransferase for deamidating high-mobility group A 1 (HMGA1) to promote fatty acid synthesis and proliferation of lung cancer cells. This post-translational modification stabilized the HMGA1 expression and enhanced the formation of the apelin-HMGA1-SREBP1 complex to facilitate SREBP1 activity for lipid metabolism and lung cancer cell growth. We uncovered the pivotal role of apelin-mediated deamidation of HMGA1 in lipid metabolism and tumorigenesis of lung cancer cells.© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [1]Department of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory of Sichuan Province, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [2]Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, China.

通讯作者：

通讯机构： [1]Department of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Precision Medicine Key Laboratory of Sichuan Province, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [*1]Department of Respiratory and Critical Care Medicine, 37 Guoxue Alley, Wuhou district, West China Hospital of Sichuan University, Chengdu 610041, China. [*2]Institute of Respiratory Health, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, 88 Keyuan South Road, Wuhou District, Chengdu 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Lipid metabolism and cancer. [2]Cancer Focus Lipid metabolism and cancer [3]Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy [4]Targeting lipid metabolism with natural products: A novel strategy for gastrointestinal cancer therapy [5]Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. [6]Blood lipid metabolism and the risk of gallstone disease: a multi-center study and meta-analysis [7]Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis [8]Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma [9]Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. [10]Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis